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The bulletin presents key findings from the third 
drug prevalence survey of households in Ireland and 
Northern Ireland. The survey sampled a representative 
number of people aged between 15 and 64 during 
late 2010 and early 2011. The survey was carried out 
according to standards set by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA).
Data relating to drug prevalence on a lifetime, last  
year (recent) and last month (current) basis for  
Ireland, Northern Ireland and the island of Ireland  
are presented in this bulletin. Statistically significant 
changes in prevalence rates between 2002/3,  
2006/7 and 2010/11 are presented in the tables  
and comparisons between 2006/7 and 2010/11  
are discussed at the end of each results section.
Key findings
n	 In Ireland, just over 27% reported 
using any illegal drugs in their lifetime. 
Cannabis was the most commonly 
used illegal drug with 25% of the 
adult population having ever used the 
drug. After cannabis, lifetime use was 
highest for ecstasy, cocaine and magic 
mushrooms (each 7%), followed by 
amphetamines (5%), LSD and poppers 
(each 4%). Less than 1% reported 
having ever used crack (0.6%), heroin 
(0.8%) or methadone (0.5%).
n In Northern Ireland more than one in 
four people surveyed (27%) reported 
having ever used any illegal drug; 
cannabis was the most commonly 
reported used illegal drug with 24% of 
respondents reporting having ever used 
it. The next most commonly reported 
illegal drugs were: poppers and ecstasy 
(each 9%); cocaine powder (6%); 
amphetamines and magic mushrooms 
(each 6%); LSD (5%); solvents (4%); 
crack (0.9%); and heroin (0.4%).
n In Ireland the lifetime prevalence rate 
for any illegal drugs was highest among 
those aged 25-34 years (42%) followed 
by the 35-44 (29%) and 15-24 (27%) 
age groups.
n In Northern Ireland lifetime use of any 
illegal drug ranged from 8% of adults 
aged 55-64 to 43% of those aged 
25-34.
n A higher proportion of men than women 
continue to report lifetime, last year 
and last month use of any illegal drugs 
in Ireland. There is no indication of a 
narrowing of the gender gap in illegal 
drug use since the last survey.
n In Northern Ireland around one in three 
males (32%) and one in five females 
(22%) had ever used any illegal drug.
n In Ireland, drugs in the category ‘Other 
opiates’ are used by more than one in 
three respondents. The rate of last year 
use of other opiates is highest among 
women and among those aged 25-34 
years.
n Women and older adults continue to 
report higher levels of use of sedatives 
or tranquillisers and anti-depressants in 
Ireland.
n In Northern Ireland over one fifth of 
respondents reported having ever used 
sedatives and tranquillisers (21%) and 
anti-depressants (22%).
n On the island of Ireland 27% of all 
adults (15-64 years) reported taking  
any illegal drug at some point in their 
life. Cannabis was the most commonly 
used illegal drug with 25% of the 
population on the island having ever 
used the drug; 6% reported having  
used cannabis in the last year and 3%  
in the last month.
n	 In Ireland lifetime use of any illegal  
drugs has increased from 24% in 
2006/7 to 27% in 2010/11 among 
all adults (15-64 yrs). Increases were 
found in lifetime use of cannabis (from 
22% to 25%) and cocaine powder 
(from 5% to 7%). The level of recent 
and current drug use has been stable 
between 2006/7 and 2010/11 for all 
illegal drugs.
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n In Northern Ireland, lifetime use and last month use of any 
illegal drug among all adults remained fairly similar between 
2006/7 and 2010/11, while last year use of any illegal drugs 
decreased from 9% in 2006/7 to 7% in 2010/11. There 
was a decrease in last year use of cannabis from 7% in 
2006/7 to 5% in 2010/11. The lifetime and last year use 
of other opiates decreased whilst there was an increase in 
the use of anti-depressants in the last year and last month 
and an increase in the lifetime and last year prevalence of 
methadone.
n While there were no significant changes in lifetime or last 
year use of alcohol since the last survey in Ireland, last 
month prevalence rates of alcohol decreased significantly 
(from 73% to 71%). There was also a significant decrease  
in the last month rate of tobacco (from 33% to 28%).
n Since the survey in 2006/7, lifetime use of any illegal drugs 
on the island of Ireland increased from 25% in 2006/7  
to 27% in 2010/11 among all adults (15-64 yrs). While 
lifetime prevalence has increased, no significant changes 
were recorded in either last year or last month use of any 
illegal drugs between 2006/7 and 2010/11.
Comparison between 2006/7 and 2010/11
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Introduction
The survey was commissioned by the National Advisory 
Committee on Drugs (NACD) in Ireland and the Public Health 
Information & Research Branch (PHIRB) within the Department 
of Health, Social Services and Public Safety (DHSSPS) in 
Northern Ireland.
The main focus of the survey was to obtain prevalence rates for 
key illegal drugs, such as cannabis, ecstasy, cocaine and heroin 
on a lifetime (ever used), last year (recent use), and last month 
(current use) basis. Similar prevalence questions were also 
asked of alcohol, tobacco, and other drugs (e.g. tranquillisers); 
attitudinal and demographic information was also sought from 
respondents.
Methodology
The questionnaire and methodology for this general population 
survey were based on best practice guidelines drawn up by the 
EMCDDA. The questionnaires were administered through face-
to-face interviews with respondents aged between 15 and 64 
years and who are normally resident in households in Ireland 
and Northern Ireland. Thus persons outside these age ranges, or 
who do not normally live in private households, have not been 
included in the survey (for example prisons, nursing homes etc.).
Fieldwork for the survey was carried out between October 2010 
and May 2011 and the final achieved sample comprised of 
7,669 respondents (5,134 in Ireland and 2,535 in Northern 
Ireland). The response rate for the survey was 60% in Ireland 
and 67% in Northern Ireland. Areas based sampling was applied 
in Ireland. The first stage involved stratifying by Health Board in 
Ireland1. In Northern Ireland, the first stage involved stratifying 
by Health and Social Care Trust and within the strata, simple 
random sampling was used. The achieved sample was weighted 
by gender, age, region2 in Ireland and by Health and Social Care 
Trust area in Northern Ireland3 to maximise its representativeness 
of the general population. The effects of stratification, clustering 
and weighing have been incorporated in the interval estimates  
(i.e. intervals are design effect adjusted). Details of the 
methodology have been summarised in a paper published 
on the websites of the NACD (http://www.nacd.ie/) and the 
DHSSPS (http://www.dhsspsni.gov.uk/) and a comprehensive 
technical report containing copies of the questionnaires used  
in both jurisdictions will be published separately.
Interviews were conducted using computer-assisted personal 
interviewing (CAPI). These techniques allow interviews to be 
conducted more efficiently and more accurately than other 
techniques such as pen-and-paper completion.
Please note:
n Prevalence rates for ‘any illegal drugs’ refers to the reported 
use of one or more of the following: amphetamines, 
cannabis, cocaine powder, crack, ecstasy, heroin, LSD,  
magic mushrooms, poppers or solvents.
n In terms of comparisons between the surveys, tests 
of statistical significance for differences between the 
prevalence of ‘Other opiates’ are not reported. As a result 
of measurement changes between 2006/7 and 2010/11, 
the ‘Other opiates’ category is not comparable between the 
surveys. The measurement of ‘Other opiates’ in Ireland in 
2002/3 included nine drugs: Opium, Temgesic®, Diconal®, 
Napps, MSTs®, Pethidine, DF118®, (Dihydrocodeine), 
Buprenorphine and Morphine. In 2006/7 the category  
‘Other opiates’ was extended to be consistent with Northern 
Ireland and included: Codeine, Feminax, Kapake, Diffs, 
Dikes, Peach, Fentanyl (Durogesic®, Sublimaze®, Actiq®), 
Oxycodone (Oxycontin®, Oxynorm®), and Buprehnorphine 
(Subutex®). In 2010/11 the category ‘Other opiates’ also 
asked specifically about substances containing codeine 
such as Maxilief, Migraleve, Nurofen Plus, Codeine Phosp, 
Panadeine, Paracetamol/Caffeine/Codeine and Doxylamine, 
Paracodin, Paramol, Solpadeine, Solpadol, Syndol, Tylex, 
Uniflu Plus, Veganin Plus.
n In the Republic of Ireland the measurement of New 
Psychoactive Substances included herbal smoking mixtures/
incense, party pills or herbal highs, bathsalts plant feeders or 
other powders, Kratom (Krypton), Salvia, Magic Mint, Divine 
Mint or Sally D and other new psychoactive substances 
mentioned by the respondent. In Northern Ireland, the 
category ‘Legal Highs’ includes party pills, herbal highs, party 
powders, Kratom and Salvia Divinorum; it does not include 
mephedrone as it is asked about separately.
1 Since January 2005 the Health Boards in Ireland have been restructured and merged under one authority, the Health Service Executive. For the purpose  
of facilitating comparisons between the 2002/3, 2006/7 and the current surveys, it was decided to continue to weigh the data by the former Health Board 
areas as these correspond with the Regional Drug Task Force (RDTF) structures.
2 The composition of the population in Ireland has changed substantially since Census 2006. Given that Census 2011 information was not available when  
weights were calculated, it was decided to weight the data using 2010 population estimates. For the purpose of constructing post-stratification weights,  
Regional Authority areas were used to define regions instead of Health Board/RDTF.
3 Since the 2006/7 Survey the Health and Social Services Boards and the Health and Social Care Trusts have been restructured. In the 2010/11 the sample  
was stratified and the data has been weighted by Health and Social Care Trust areas, while in the previous two surveys the sample was stratified and the data 
was weighted by the Health and Social Services Boards that existed at the time.
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What is prevalence?
The term prevalence refers to the proportion of  
a population who have used a drug over a particular  
time period. In general population surveys, prevalence  
is measured by asking respondents in a representative 
sample drawn from the population to recall their use of 
drugs. The three most widely used recall periods are: 
lifetime (ever used a drug), last year (used a drug in the  
last twelve months), and last month (used a drug in the last 
30 days). Provided that a sample is representative of the 
total population, prevalence information obtained from a 
sample can be used to infer prevalence in the population.
Lifetime prevalence refers to the proportion of the  
sample that reported ever having used the named drug at 
the time they were surveyed. A person who records lifetime 
prevalence may or may not be currently using the drug. 
Lifetime prevalence should not be interpreted as meaning 
that people have necessarily used a drug over a long period 
of time or that they will use the drug in future.
Last year prevalence refers to the proportion of the 
sample that reported using a named drug in the year prior 
to the survey. Last year prevalence is often referred to as 
recent use.
Last month prevalence refers to the proportion of the 
sample that reported using a named drug in the 30 day 
period prior to the survey. Last month prevalence is often 
referred to as current use. A proportion of those reporting 
current use may be occasional (or first-time) users who 
happen to have used in the period leading up to the survey. 
It should therefore be appreciated that current use is not 
synonymous with regular use.
As with other European surveys, people over the age of  
64 are excluded from this survey, as they grew up in an era 
when both the use and availability of illegal drugs were very 
limited. Therefore surveys with older people have, to date, 
shown very low rates of use even on a lifetime basis. This 
situation will change over time as the younger population 
grows older. Hence lifetime prevalence rates are likely to 
increase for a considerable period of time. When examining 
the data and comparing results over time, last year use is 
the best reflection of changes as it refers to recent use. Last 
month use is equally valuable as it refers to current use.
Understanding the results  
of this bulletin
Results (revised) from the first (October 2003, revised June 
2005) and second Drug Prevalence Surveys (January 2008) 
were previously published and gave lifetime, last year, and last 
month prevalence rates for key drugs for the island of Ireland, 
Ireland and Northern Ireland.
The tables for this bulletin report drug prevalence rates  
for 2002/3, 2006/7 and 2010/11. Results are given for  
all respondents, and are also presented by gender and age.  
The results from comparing 2010/11 survey results with the 
2006/7 and 2002/3 survey results are presented in the tables 
in this bulletin. Only 2010/11 and 2006/7 comparisons are 
discussed in the accompanying text.
The figures for Ireland in 2002/3 and 2006/7 reported in 
this bulletin may differ slightly from figures report in earlier 
publications. These differences are due to applying new 
estimation procedures which were necessary to ensure the 
comparability between 2002/3, 2006/7 and 2010/11 drug 
prevalence survey data.
All prevalence rates presented in the accompanying tables 
are rounded to one decimal place and are rounded to whole 
numbers in the text. Where it provides for a better understanding 
of the situation figures in the text are sometimes reported at one 
decimal place (e.g. small/low figures).
As in all sample surveys, the greater the sample size the more 
statistically reliable are the results. Some of the differences in 
prevalence rates in the tables will be attributable to natural 
sample variations. Details of confidence intervals for all of the 
figures contained in this bulletin can be found on the websites  
of the NACD and DHSSPS.
Invalid responses have been excluded from all analyses. Percentages 
may not always sum to 100 due to either the effect of rounding 
or where respondents could give more than one answer.
When the figure 0.0% appears it does not mean that no-one 
in the population has used the drug, rather it means that in this 
category no respondent reported use. The confidence intervals 
will provide a range of likely prevalence rates for all categories  
of drug use.
The island of Ireland data was derived from the combined data 
from Northern Ireland and Ireland.
Statistical significance
Statistical significance tests (Newcombe-Wilson Hybrid) have been 
used for this bulletin and changes that are found to be statistically 
significant are reported. When considering the results it should 
be borne in mind that statistical significance does not imply that 
the change is of practical importance. This importance is reflected 
in an evaluation of effect size, which is a substantive issue.
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The tests of statistical significance are used to establish the 
degree of confidence with which we can infer that the observed 
changes in drug prevalence between 2010/11 and 2006/7 and 
between 2010/11 and 2002/3 are not due to sampling error. A 
significance level of 5% has been specified which means that the 
likelihood that sampling error accounts for the observed change 
is less than 5%.
A general population drug prevalence survey has some 
limitations. As mentioned above, some groups with high  
drug use prevalence are not covered by this type of survey 
(for example the homeless, those in prison). Drug prevalence 
questions are considered to be sensitive and therefore people 
may refuse to participate or under-report their drug use. Moreover, 
for some groups the numbers included in the sample are too 
small for reliable prevalence estimations. General population 
prevalence estimates are therefore supplemented by other 
methods (e.g. capture-recapture for problem drug use and 
surveys targeting special populations (e.g. prisoners, students, 
early school leavers).
Results – Ireland
Key findings
n Of all adults in Ireland, just over 27% reported using any 
illegal drugs in their lifetime. Seven percent reported using 
any illegal drugs in the year prior to the survey (last year)  
and 3% reported use in the month prior to the survey  
(last month).
n Cannabis was the most commonly used illegal drug with 
25% of the adult population having ever used the drug;  
6% reported using cannabis in the last year and 3% 
reported use in the last month.
n Lifetime prevalence of all other illegal drugs was considerably 
lower than cannabis. For other illegal drugs highest lifetime 
use was reported for ecstasy, cocaine and magic mushrooms 
(each 7%), followed by amphetamines (5%), LSD and 
poppers (each 4%). Less than 1% reported having ever 
used crack (0.6%), heroin (0.8%) or methadone (0.5%).
n The lifetime prevalence rate for any illegal drugs was  
highest among those aged 25-34 years (42%) followed  
by the 35-44 (29%) and 15-24 (27%) age groups.
n A higher proportion of men than women continue to report 
lifetime, last year and last month use of any illegal drugs.
n There is no indication of a narrowing of the gender gap in 
illegal drug use.
n Other opiates are used by more than one in three 
respondents. The rate of last year use of other opiates is 
highest among women and among those aged 25-34 years.
n Women and older adults continue to report higher levels  
of use of sedatives or tranquillisers and anti-depressants.
n Lifetime prevalence rates have increased between 2006/7 
and 2010/11 for any illegal drug use and a number of 
specific drugs including cannabis and cocaine. The level 
of current and recent drug use has been stable between 
2006/7 and 2010/11 for all illegal drugs.
n While there are no statistically significant changes in lifetime 
or last year use of alcohol since the last survey, there has 
been a statistically significant decrease in last month use  
of alcohol from 73% to 71% and of tobacco use from  
33% to 28%.
Ireland – Lifetime prevalence (see Table 1.1)
Results from the survey indicated that just over one in four 
(27%) of the population aged 15-64 years in Ireland have  
used an illegal drug in their lifetime.
Drug type
Cannabis use was the most commonly used illegal drug with 
25% of the population having ever used the drug. Among other 
drugs, lifetime prevalence was highest for ecstasy, cocaine (total), 
magic mushrooms (each 7%), followed by amphetamines (5%), 
poppers (4%) and solvents (3%). Less than 1% reported having 
ever used crack (0.6%), heroin (0.8%) or methadone (0.5%).
Over one third of respondents reported lifetime use of other 
opiates (39%). Lifetime use of sedatives or tranquillisers was 
reported by 14% and anti-depressants by 10% of respondents.
Gender (see Table 1.2)
Lifetime use of any illegal drug was substantially higher among 
men (36%) than women (19%). Men were between three and 
four times more likely to report lifetime use of poppers (6% vs 
2%), LSD (7% vs 2%) and solvents (4% vs 1%). Men were 
at least twice as likely to report lifetime use of cocaine, ecstasy, 
magic mushrooms (each 10% vs 4%) and amphetamines  
(7% vs 3%). For cannabis, lifetime use was almost twice as  
high for men (33%) than women (18%).
Women were more likely than men to report use of other 
opiates (42% vs 35%), sedatives or tranquillisers (16% vs 12%) 
and anti-depressants (12% vs 8%).
Age (see Table 1.4)
The highest lifetime prevalence for use of any illegal drugs 
was recorded amongst those aged 25-34 (42%) followed by 
the 35-44 (29%) and 15-24 (27%) age groups. Those aged 
between 25-34 years report highest lifetime prevalence of cannabis 
(39%), cocaine (13%), amphetamines (8%), ecstasy (15%), 
LSD (8%), magic mushrooms (12%), solvents (5%) and poppers 
(8%) while use of other opiates (42%) is most prevalent among 
those aged 35-44 years. Heroin (1%), methadone (1%) and 
anti-depressants (14%) are highest among those aged 45-54 
year, while sedatives or tranquillisers is highest among those 
aged 55-64 years (21%).
Drug use in Ireland and Northern Ireland: first results from the 2010/11 Drug Prevalence Survey
7National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch (PHIRB)
Ireland – Last year prevalence (see Table 1.1)
The overall prevalence rate for last year use of any illegal drugs 
was 7% in Ireland.
Drug type
With regard to drug use in the year prior to the survey, cannabis 
was the most frequently reported illegal drug (6%). After 
cannabis, new psychoactive substance (4%) and cocaine 
(1.5%) were the next most widely used in Ireland. Less 
than one percent of those surveyed reported last year use 
of amphetamines, ecstasy, LSD, magic mushrooms, solvents, 
poppers, heroin and methadone.
Last year prevalence of other opiates was 28%, the rate for 
sedatives or tranquillisers was 7% and for anti-depressants  
it was 4%.
Gender (see Table 1.2)
Use of any illegal drug in the 12 months prior to the survey was 
higher among men (10%) than women (4%). Men were three 
times more likely than women to report last year use of cannabis 
(9% vs 3%) and new psychoactive substances (5.4% vs 1.6%) 
and cocaine powder (2.3% vs 0.7%).
Women (32%) were more likely than men (24%) to report use 
of other opiates in the last year.
Age (see Tables 1.3 and 1.4)
People aged between 15-24 years reported the highest last year 
use of any illegal drug (15%) followed by those aged between 
25-34 years (10%) and the 35-44 years old (4%). Those aged 
15-24 years also reported the highest use of cannabis (13%), 
new psychoactive substances (10%), amphetamines (1.5%), 
ecstasy (1.1%) and magic mushrooms (1%). Use was also 
highest in this age group for many other drugs, for most of 
which, last year prevalence rates were less than one percent.
Among those aged 25-34 years, last year use of other opiates 
(31%) and cocaine (3%) was highest. Last year use of sedatives 
or tranquillisers was highest among the 55-64 age group (10%) 
and for anti-depressants, use was highest among those aged 
between 45-54 years (7%).
Ireland – Last month prevalence (Table 1.1)
In the month preceding the survey, 3% of the population 
reported using any illegal drugs.
Drug type
In Ireland cannabis (3%) was the most commonly used illegal 
drug in the month preceding the survey. After cannabis, the most 
commonly used illegal drugs in the last month were cocaine 
(0.5%) followed by methadone (0.2%), amphetamines, ecstasy, 
solvents, poppers and heroin (each 0.1%).
The rate of last month use of other opiates was 14%, the rate 
for sedatives or tranquillisers was 3% and for anti-depressants, 4%.
Gender (Table 1.2)
The last month prevalence rate for any illegal drugs was 5% 
among men and 1% among women. Men were also over  
5 times more likely to report use of cannabis in the last month. 
Men were more than twice as likely to use cocaine (0.8%) than 
women (0.3) in the last month.
Last month use of other opiates was substantially higher  
among women (17%) when compared to men (11%).  
Use of anti-depressants was higher among women (5% vs 3%)  
as was use of sedatives or tranquillisers (3% vs 2%).
Age (Tables 1.3 and 1.4)
The two youngest age groups reported the highest rate of last 
month use of any illegal drugs. Among the 15-24 age group 
last month use of any illegal drug was 6%, followed by 5% 
among those aged between 25-34 years. This rate declined with 
age thereafter. The prevalence of last month cannabis use was 
highest among the 15-24 age group (5%). Last month use of 
cocaine powder was highest among the 25-34 age group (1.3%).
The highest rate of last month prevalence of other opiates was 
among those aged 35-44 years at 16%. Use of sedatives or 
tranquillisers is highest among those aged 55-64 yrs (7%) and 
anti-depressants were most commonly used in the last month  
by the 45-54 age group (6%).
Gender and age (Table 1.5a – 1.5c)
Although lifetime prevalence for any illegal drug is higher  
among men than women, the pattern of lifetime use between 
the age groups is the same for men and women. For both men 
and women lifetime use is highest among those aged 25-34 
years, followed by use among those in the 35-44 and 15-24 
age groups. For men and women last year and last month 
prevalence of any illegal drug is highest among the youngest 
age group (15-24 yrs) and decreases with age. The same pattern 
holds for new psychoactive substances (last year use only).
Results – Ireland
Comparison 2006/7 – 2010/11 
Significant changes (See Tables 1.1 – 1.3)
Any illegal drugs
Since the survey in 2006/7, lifetime use of any illegal drugs 
increased from 24% in 2006/7 to 27% in 2010/11 among 
all adults (15-64 yrs) in Ireland. Use among males increased 
from 30% to 36% while lifetime prevalence among females 
remained stable at 19%. For younger respondents (15-34 yrs) 
lifetime prevalence increased from 31% to 36% and for the 
older group (35-64 yrs) it increased from 18% to 21%. While 
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lifetime prevalence has increased, no significant changes in either 
last year or last month use of any illegal drugs were recorded 
between 2006/7 and 2010/11.
When considering the importance of changes in lifetime 
since the last survey, it should be borne in mind that lifetime 
prevalence of illegal drug use is higher among more recent birth 
cohorts than earlier birth cohorts, indicating the influence of a 
cohort effect.
Cannabis
Lifetime prevalence of cannabis use increased from 22% to 
25% among all adults (15-64 yrs) since 2006/7. For men 
lifetime use of cannabis increased from 27% to 33% while 
it remained stable for women around 17%. For younger 
respondents (15-34 yrs), lifetime prevalence increased from 
29% to 33% and for the older group (35-64 yrs), from 16%  
to 19%. There are no significant changes in either last year or 
last month use of cannabis since 2006/7.
Cocaine
Lifetime use of cocaine powder increased from 5% to 7% 
among all adults (15-64 yrs) since the last survey. Significant 
increases of lifetime use of cocaine powder are also recorded 
for men (7% to 10%) and for the older age group (35-64 yrs) 
of respondents (3% to 5%). There are no significant changes in 
either last year or last month use of cocaine powder.
Alcohol and tobacco
While there were no significant changes in lifetime or last 
year use of alcohol since the last survey, last month use of 
alcohol significantly decreased from 73% to 71%. There are 
no significant changes as far as men’s drinking is concerned but 
women’s drinking in the last month declined from 68% to 65%. 
Last year prevalence of alcohol among older adults (35-64 yrs) 
increased from 82% to 85%.
Since the last survey no significant changes were found in 
lifetime or last year prevalence rates of tobacco use. The rate 
of last month use of tobacco decreased significantly from 33% 
to 28%. Among women last year use of tobacco declined from 
36% to 29% and last month use declined from 32% to 25%. 
No significant changes were found in men’s tobacco use since 
the last survey.
Among older adults (35-64 yrs) last year and last month 
prevalence of tobacco decreased significantly. Last year 
prevalence decreased from 32% to 29% and the rate of last 
month prevalence for this age group also declined from 30%  
to 26%. Among younger adults (15-34 yrs) last month rates  
of tobacco use decreased from 36% to 31%.
Other significant changes
Table 1.1 shows that since the last survey there have been 
significant increases among all adults’ (15-64 yrs) lifetime  
use of amphetamines (+1 percentage points), ecstasy  
(+1.4 percentage points), LSD (+ 1.5 percentage points) 
and sedatives or tranquillisers (+3.3 percentage points). When 
considering the importance of changes in lifetime since the last 
survey, it should be borne in mind that lifetime prevalence of 
illegal drug use is higher among more recent birth cohorts than 
earlier birth cohorts, indicating the influence of a cohort effect.
Since 2006/7 there were significant increases in last year 
prevalence for sedatives or tranquillisers (+1.8 percentage 
points) and solvents from (+0.1 percentage points). Significant 
increases in last month prevalence are found only for anti-
depressants (+0.9 percentage points). Significant decreases 
were recorded for last year prevalence of ecstasy (-0.7 percentage 
points) and poppers (-0.3 percentage points) and last month 
use decreased for ecstasy (-0.2 percentage points).
For men (Table 1.2) there has been an increase in lifetime 
use of amphetamines (+2.0 percentage points), LSD (+2.6 
percentage points), solvents (+1.5 percentage points), sedatives 
or tranquillisers (+4.3 percentage points) and anti-depressants 
(+2.4 percentage points). Sedatives or tranquillisers are the only 
drugs for which there is a significant increase (+2 percentage 
points) in men’s use in the last year. A significant decrease was 
found for men’s use of ecstasy in the last year (-1.2 percentage 
points) and for last month (-0.4 percentage points). Among 
women, sedatives or tranquillisers are the only drugs for which 
a significant increase was found and this for both lifetime use 
(+2.3 percentage points) and last year use (+ 1.6 percentage 
points). There are no significant changes for last month use.
Table 1.3 shows that among younger adults (15-34 years) since 
the last survey there has been an increase in lifetime use of LSD 
(+1.7 percentage points) and sedatives or tranquillisers (+4.2 
percentage points). For this age group there is also an increase 
in last year use of sedatives or tranquillisers (2.2 percentage 
points). Decreases in last year use were found for poppers  
(-0.7 percentage points) and ecstasy (-1.5 percentage points). 
Last month use of ecstasy among younger adults decreased 
(-0.5 percentage points).
Among older adults (35-64 years) there has been an increase 
in the lifetime use of ecstasy (+1.4 percentage points), LSD 
(+1.5 percentage points), magic mushrooms (+1.7 percentage 
points), solvents (+.7 percentage points), sedatives or 
tranquillisers (+2.2 percentage points) and anti-depressants 
(+2.1 percentage points). However there are no significant 
changes for last year use among older adults. Of all drugs used 
in the last month, anti-depressants are the only ones for which 
a significant change (+1.5 percentage points) is found since the 
last survey.
Drug use in Ireland and Northern Ireland: first results from the 2010/11 Drug Prevalence Survey
9National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch (PHIRB)
Results – Northern Ireland
Key findings
n More than one in four people surveyed (27%) reported 
having ever used any illegal drug; seven percent reported 
using any illegal drug in the year prior to the survey; and  
less than one in twenty (3%) respondents reported using 
any illegal drug in the month prior to the survey.
n Cannabis was the most commonly reported illegal drug  
used with 24% of respondents reporting having ever used  
it; one in twenty (5%) respondents reported cannabis use  
in the last year and 3% of respondents reported use in  
the last month.
n After cannabis, the most commonly reported illegal drugs 
ever used were: poppers and ecstasy (each 9%); cocaine 
powder (6%); amphetamines and magic mushrooms (each 
6%); LSD (5%); solvents (4%); crack (0.9%); and heroin 
(0.4%).
n Around one in three males (32%) and one in five females 
(22%) had ever used any illegal drug. Similar results were 
found for cannabis use, 29% of males and 19% of females 
had ever used cannabis.
n Nearly two fifths of young adults (15-34 years) had ever 
used any illegal drugs compared with one fifth (20%) of 
older adults (35-64 years). The lifetime prevalence rates for 
any illegal drug ranged from 8% of those aged 55-64 to 
43% of those aged 25-34.
n Over one fifth of respondents reported having ever used 
sedatives and tranquillisers (21%) and anti-depressants 
(22%). Nearly one quarter (24%) of females reported 
lifetime use of sedatives and tranquillisers compared with 
17% of males, and nearly three in ten (28%) females 
reported lifetime use of anti-depressants compared with 
15% of males.
n In Northern Ireland, lifetime use and last month use of any 
illegal drug among all adults remained fairly similar between 
2006/7 and 2010/11, while the last year use of any illegal 
drugs decreased from 9% in 2006/7 to 7% in 2010/11.
n Since 2006/7 there was a decrease in last year use  
of cannabis from 7% in 2006/7 to 5% in 2010/11  
and a decrease in the lifetime and last year use of other 
opiates. The use of anti-depressants in the last year and  
last month has increased and the lifetime and last year  
use of methadone has increased.
Northern Ireland – Lifetime prevalence  
(Table 2.1)
Results from the survey indicated that more than one quarter 
(27%) of the Northern Ireland population aged 15-64 have ever 
used any illegal drugs.
Drug type
Cannabis was the most commonly reported illegal drug ever 
used, with 24% of respondents reporting lifetime use. Lifetime 
prevalence rates of other illegal drugs were: poppers and ecstasy 
(each 9%); cocaine powder (6%); amphetamines and magic 
mushrooms (each 6%); LSD (5%); and solvents (4%). Less 
than one percent of respondents reported ever using crack 
(0.9%) and heroin (0.4%).
Sixteen percent of respondents reported lifetime use of other 
opiates, and over one fifth of respondents reported lifetime use 
of sedatives and tranquillisers (21%) and anti-depressants (22%).
The lifetime prevalence rate was 2% for both mephedrone  
and legal highs.
Gender (Table 2.2)
Around one in three (32%) males compared with over one  
in five females (22%) had ever used any illegal drug.
Approximately three in ten males (29%) compared with two  
in ten females (19%) had ever used cannabis. Around one  
in ten males reported lifetime use of cocaine (including crack) 
(9%), amphetamines (8%), ecstasy (11%), LSD (7%), magic 
mushrooms (9%) and poppers (10%) compared with about 
one in twenty females reported having ever used cocaine 
(including crack) (5%), amphetamines (5%), ecstasy (6%),  
LSD (3%), magic mushrooms (3%) and poppers (8%).
Less than one in four (24%) females reported lifetime use  
of sedatives and tranquillisers compared with less than one in 
five (17%) males. Nearly three in ten (28%) females reported 
having ever used anti-depressants compared with 15% of males. 
Fourteen percent of males compared with 17% of females 
reported lifetime use of other opiates.
Age (Tables 2.3 and 2.4)
Nearly two fifths (37%) of young adults (15-34 years) had ever 
used any illegal drug compared with one fifth (20%) of older 
adults (35-64 years). The lifetime prevalence rates for any illegal 
drug ranged from 8% of those aged 55-64 to 43% of those 
aged 25-34.
The lifetime use of cannabis results showed that nearly one in 
three (32%) young adults (aged 15-34) had ever used cannabis 
compared with nearly one in five (18%) older adults (aged 
35-64). The lifetime prevalence rates for cannabis ranged from 
7% of those aged 55-64 to 38% of those aged 25-34.
Over one in ten young adults (15-34 years) had used cocaine 
(including crack) (11%), ecstasy (14%) and poppers (14%) 
compared with around one in twenty older adults (35-64 years) 
had used cocaine (including crack) (3%), ecstasy (5%) and 
poppers (5%).
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The lifetime prevalence rates for sedatives and tranquillisers and 
anti-depressants showed that over one quarter of older adults 
(aged 35-64) had used them (26% and 28%, respectively) 
compared with 14% of young adults aged 15-34 (for both drug 
categories). The lifetime prevalence rates for other opiate was 
13% for young adults aged 15-34 and 18% for older adults 
aged 35-64.
The lifetime prevalence rate for adults aged 15-24 was 6%  
for both mephedrone and legal highs.
Northern Ireland – Last year prevalence 
(Table 2.1)
The overall prevalence rate for the use of any illegal drug  
in the year preceding the survey was 7%.
Drug type
In the year preceding the survey cannabis was the most 
commonly reported illegal drug used, with one in twenty 
respondents reporting its use (5%). Following cannabis, the 
most frequently reported illegal drugs used were cocaine 
(including crack) (2%), amphetamines and ecstasy (each 1%), 
poppers (0.8%).
Six percent of respondents reported last year use of other opiates, 
approximately one in ten respondents reported last year use of 
sedatives and tranquillisers (11%) and anti-depressants (12%).
One percent of respondents had used mephedrone and legal 
highs in the year preceding the survey.
Gender (Table 2.2)
Around one in ten male respondents (9%) compared with 
nearly one in twenty (4%) female respondents had used 
any illegal drug in the last year. Similar results were found for 
cannabis use with 7% of males and 3% of females having used 
it in the last twelve months.
Thirteen percent of females compared with 9% of males  
had used sedatives and tranquillisers in the last year. Similarly, 
15% of females compared with 9% of males had used anti-
depressants in the year preceding the survey. Males and females 
had similar last year prevalence rates for other opiates (6% and 
7%, respectively).
Age (Tables 2.3 and 2.4)
Around one in ten respondents aged 15-24 years (13%) 
and 25-34 years (10%) had used any illegal drug in the year 
preceding the survey, the corresponding figures for those in the 
older age groups are 5% of those aged 35-44 years, 2% of 
those aged 45-54 years and 0.3% of those aged 55-64 years.
Less than one in ten young adults aged 15-34 years (9%) had 
used cannabis in the year preceding the survey compared with 
2% of older adults aged 35-64 years. While, approximately 
one in seven older adults aged 35-64 had used sedatives and 
tranquillisers (14%), and anti-depressants (16%) compared with 
6% of young adults aged 15-34 reported using sedatives and 
tranquillisers in the last year and 7% of young adults aged 15-34 
with last year use of anti-depressants. The last year prevalence 
rate for other opiates was 6% for those aged 15-34 and 7%  
for those aged 35-64.
Northern Ireland – Last month prevalence 
(Table 2.1)
In the month prior to the survey the prevalence rate for the use 
of any illegal drug was 3%.
Drug type
Cannabis (3%) was the most commonly reported illegal drug 
used in the month prior to the survey. Following cannabis, the 
most commonly reported illegal drugs used in the last month 
were cocaine (including crack) (0.5%), amphetamines and 
ecstasy (each 0.3%) and poppers (0.1%).
The prevalence rate for last month use of anti-depressants was 
10%, and 8% for sedatives and tranquillisers. Four percent of 
respondents reported using other opiates in the month prior  
to the survey.
The last month prevalence rate for mephedrone was 0.1%  
and 0.2% for legal highs.
Gender (Table 2.2)
The last month prevalence rate of any illegal drug was 5% for 
males and 2% for females. Four percent of males had used 
cannabis in the last month compared with 1% of females. Half  
a percent (0.5%) of males and 0.1% of females had ecstasy 
use in the last month.
Nine percent of females compared with 7% of males reported 
having used sedatives and tranquillisers in the last month. 
Similarly, 13% of females compared with 8% of males had used 
anti-depressants in the month preceding the survey. Males and 
females had similar last month prevalence rates for other opiates 
(3% and 4%, respectively).
Age (Tables 2.3 and 2.4)
Last month prevalence for the use of any illegal drug was 6% 
for young adults aged 15-34 years compared with 2% for older 
adults aged 35-64.
Five percent of young adults (15-34 years) had used cannabis in 
the last month compared with 1% of older adults (35-64 years). 
Last month use of ecstasy was 0.6% for young adults aged 
15-34 compared with 0.1% for older adults aged 35-64.
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More than one in ten older adults (35-64 years) had last month 
use of sedatives and tranquillisers (11%) and anti-depressants 
(14%) compared with 4% and 5% (respectively) for young 
adults (15-34 years). Less than one in twenty young adults 
(aged 15-34) and older adults (aged 35-64) had used other 
opiates in the last month (3% and 4%, respectively).
Less than half a percent of young adults (15-34 years) had  
used mephedrone (0.1%) and legal highs (0.4%) in the  
month prior to the survey.
Northern Ireland – Results comparison 
2006/7-2010/11
All findings reported are statistically significant at least at the  
5% level.
Significant changes (Tables 2.1 – 2.3)
Any illegal drugs
Since the 2006/7 survey, there has been a decrease in last 
year prevalence of using any illegal drug. Last year prevalence 
decreased from 9.4% in 2006/7 to 6.6% in 2010/11. Last 
year use of any illegal drug for males decreased from 13.7% 
to 9.2%, while no significant change was observed for females. 
This decrease in last year use was also observed for those aged 
15-34 years, with prevalence decreasing from 17.3% to 11.8%. 
No significant change was observed for those aged 35-64 years. 
There were no significant changes in lifetime prevalence or last 
month prevalence of any illegal drug.
Cannabis
Last year prevalence of cannabis use decreased from 7.2%  
in 2006/7 to 5.1% in 2010/11. For those aged 35-64 years, 
last year use of cannabis decreased from 3.3% to 1.9%. There 
were no significant changes in last year cannabis use for males 
or females and for those aged 15-34 years. There were no 
significant changes in lifetime or last month prevalence for 
cannabis use.
Other significant changes
Table 2.1 shows that there have been a number of significant 
changes since the 2006/7 survey. Lifetime prevalence of 
methadone use was shown to have increased (from 0.1% 
to 1.0%) while there was a decrease in lifetime use of other 
opiates (from 20.2% to 15.6%). Last year prevalence showed 
similar changes for these drugs: last year methadone use 
increased from 0.0% to 0.4% while there was a decrease in 
use of other opiates (from 8.4% to 6.4%). Last year use of anti-
depressants increased (from 9.1% to 12.0%), as did last month 
use of anti-depressants (from 7.5% to 10.2%).
Among males (Table 2.2) significant increases were observed 
for lifetime use of methadone (from 0.1% to 1.5%) and crack 
(from 0.4% to 1.2%). Last year prevalence of methadone 
also increased among males (from 0.0% to 0.6%). There 
was a significant increase in last year use of anti-depressants 
among males (from 5.8% to 8.9%) and last month use of anti-
depressants (from 4.2% to 7.6%).
Among women, there was an increase in lifetime use of solvents 
(from 2.0% to 3.7%) and poppers (from 4.9% to 7.6%), while 
there was a decrease in lifetime use of other opiates (from 
23.0% to 17.4%).
Among younger adults (15-34 years) there has been an increase 
in lifetime use of methadone since the 2006/7 survey (from 
0.1% to 2.0%). This increase was also observed for last year 
use of methadone among this age group (from 0.0% to 0.8%). 
Lifetime prevalence of LSD has decreased among those aged 
15-34 years (from 9.4% to 5.7%).
Among older adults (35-64 years) there has been an increase 
in lifetime use of ecstasy (from 2.9% to 4.8%) and poppers 
(from 3.4% to 5.2%). There was a decrease in the prevalence 
of other opiates across all three time periods, lifetime prevalence 
decreased from 24.7% to 17.6%, last year prevalence decreased 
from 9.3% to 6.9% and last month prevalence decreased from 
5.8% to 4.0%. Among this age group there was an increase in 
last year prevalence of anti-depressants (from 11.7% to 15.7%) 
and last month prevalence of anti-depressants (from 10.0% to 
14.0%).
Results – Island of Ireland
Key findings
n On the island of Ireland 27% of all adults (15-64 years) 
reported ever having used any illegal drugs; 7% reported 
using any illegal drugs in the year prior to the survey; and 
3% reported using any illegal drugs in the month prior to  
the survey;
n Cannabis was the most commonly used illegal drug with 
25% of the population on the island having ever used the 
drug; 6% reported having used cannabis in the last year and 
3% in the last month.
n Lifetime prevalence rates for other illegal drugs on the island 
of Ireland were considerably lower than for cannabis; among 
the other drugs, lifetime prevalence was highest for ecstasy 
and cocaine (each 7%) followed by magic mushrooms (6%, 
poppers, amphetamines, LSD (each 5%) and solvents (3%).
n Since the survey in 2006/7, lifetime use of any illegal drugs 
increased from 25% in 2006/7 to 27% in 2010/11 among 
all adults (15-64 yrs) on the island of Ireland. While lifetime 
prevalence has increased, no significant changes in either 
last year or last month use of any illegal drugs were recorded 
between 2006/7 and 2010/11.
Drug use in Ireland and Northern Ireland: first results from the 2010/11 Drug Prevalence Survey
12 National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch (PHIRB)
Island of Ireland – Lifetime prevalence  
(see Table 3.1)
Results from the survey indicated that 27% of the population 
aged 15-64 years in the island of Ireland have used any illegal 
drug in their lifetime.
Drug type
Cannabis use was the most commonly used illegal drug with 
25% of the population having ever used the drug. Among 
other drugs, lifetime prevalence was highest for ecstasy and 
cocaine (total) (each 7%), followed by magic mushrooms (6%), 
poppers, amphetamines, LSD (each 5%) and solvents (3%). 
Less than 1% reported having ever used crack (0.7%), heroin 
(0.6%) or methadone (0.6%).
Lifetime use of sedatives or tranquillisers was reported by  
16% and anti-depressants by 14% of respondents.
Island of Ireland – Last year prevalence  
(see Table 3.1)
The overall prevalence rate for last year use of any illegal  
drugs was 7% in the island of Ireland.
Drug type
With regard to drug use in the year prior to the survey, cannabis 
was the most frequently reported illegal drug (6%). After 
cannabis, cocaine (1.5%) was the next most widely used  
drug on the island of Ireland. Less than one percent of those 
surveyed reported last year use of ecstasy, amphetamines,  
magic mushrooms, poppers, LSD, methadone, crack, heroin  
and solvents.
Last year prevalence for sedatives or tranquillisers was 8%  
and for anti-depressants the rate was 7%.
Island of Ireland – Last month prevalence 
(Table 3.1)
In the month preceding the survey, 3% of the population 
reported using any illegal drugs on the island of Ireland.
Drug type
On the island of Ireland, cannabis (3%) was the most 
commonly used illegal drug in the month preceding the survey. 
After cannabis, the most commonly used illegal drugs in the last 
month was cocaine (0.5%) followed by heroin, methadone, 
amphetamines, ecstasy, solvents and poppers (each 0.1%)  
and crack, LSD, magic mushrooms (0.0%)
The rate of last month use of sedatives or tranquillisers was  
4% and for anti-depressants it was 6%.
Comparison 2006/7-2010/11 
Significant changes (Table 3.1)
Any illegal drugs
Since the survey in 2006/7, lifetime use of any illegal drugs 
increased from 25% in 2006/7 to 27% in 2010/11 among 
all adults (15-64 yrs) on the island of Ireland. While lifetime 
prevalence has increased, no significant changes in either 
last year or last month use of any illegal drugs were recorded 
between 2006/7 and 2010/11.
Cannabis
Lifetime prevalence of cannabis use increased from 23% to 
25% among all adults (15-64 yrs) since 2006/7. There are  
no significant changes in either last year or last month use  
of cannabis since 2006/7.
Cocaine
Lifetime use of cocaine increased from 5% to 7% among all 
adults (15-64 yrs) since the last survey. There are no significant 
changes in either last year or last month use of cocaine powder.
Other significant changes
Table 3.1 shows that since the last survey there have been 
significant increases among all adults’ (15-64 yrs) lifetime  
use of amphetamines (+0.8 percentage points), ecstasy  
(+1.4 percentage points), sedatives or tranquillisers  
(+2.5 percentage points) and methadone (+0.3 percentage 
points). Since 2006/7 there were significant increases in last 
year prevalence for sedatives or tranquillisers (+1.8 percentage 
points), anti-depressants (+1.1 percentage points) and 
methadone (0.2 percentage points). Significant increases  
in last month prevalence are found only for anti-depressants 
(+1.5 percentage points). Significant decreases were recorded 
for last year prevalence of ecstasy (-0.7 percentage points) and 
poppers (-0.3 percentage points) and last month use decreased 
for ecstasy (-0.3 percentage points).
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Table 1.1: Prevalence of drug use (adults 15-64 yrs) in Ireland, 2002/3, 2006/7 and 2010/11
Lifetime use (%) Last year (%) Last month (%)
Drug 2002/3 2006/7 2010/11 2002/3 2006/7 2010/11 2002/3 2006/7 2010/11
Any illegal drug* 18.5 24.0 27.2ab 5.6 7.2 7.0b 3.0 2.9 3.2
Cannabis 17.3 21.9 25.3ab 5.1 6.3 6.0 2.6 2.6 2.8
Heroin 0.5 0.4 0.8a 0.1 0.1 0.1 0.1 0.0 0.1
Methadone 0.3 0.4 0.5 0.2 0.2 0.2 0.1 0.1 0.2
Other opiates† 3.0 6.2 38.8 0.5 2.2 27.9 0.2 0.9 14.2
Cocaine (including crack) 3.0 5.3 6.8ab 1.1 1.7 1.5 0.4 0.5 0.5
Crack 0.3 0.6 0.6b 0.1 0.1 0.1 0.0 0.0 0.0
Cocaine powder 2.9 5.1 6.7ab 1.1 1.6 1.5 0.4 0.5 0.5
Amphetamines 2.9 3.5 4.5ab 0.4 0.4 0.4 0.2 0.1 0.1
Ecstasy 3.7 5.5 6.9ab 1.1 1.2 0.5ab 0.3 0.3 0.1ab
LSD 2.9 2.9 4.4ab 0.1 0.1 0.3 0.0 0.0 0.0
Magic mushrooms 3.8 5.9 6.5b 0.4 0.6 0.5 0.0 0.0 0.0
Solvents 1.7 1.9 2.6b 0.1 0.0 0.1a 0.0 0.0 0.1
Poppers 2.6 3.3 3.9b 0.4 0.5 0.2a 0.1 0.1 0.1
Sedatives or tranquillisers ** 10.6 13.9a ** 4.7 6.5a ** 3.0 2.8
Anti-depressants ** 9.3 10.4 ** 4.4 4.8 ** 3.2 4.1a
New psychoactive substances *** *** *** *** *** 3.5 *** *** ***
Tobacco 60.0 57.9 56.7b 38.0 36.3 32.5ab 33.2 32.6 28.3ab
Alcohol 90.1 90.2 90.3 83.3 84.0 85.3 73.9 73.2 70.6ab
a Significant change (p<.05) between 2006/7 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
b Significant change (p<.05) between 2002/3 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** In 2002/3 the survey asked about use of sedatives, tranquillisers or anti-depressants together. Since 2006/7 the survey has asked about sedatives/tranquillisers and anti-depressants separately.
*** In 2010/11 the survey asked respondents about their use of New Psychoactive Substances for the first time. The survey asked about use in the last 12 months only.
† Tests for statistical significance between the prevalence of ‘Other opiates’ are not reported. As a result of measurement changes in 2006/7 and 2010/11, the ‘Other opiates’ category is not comparable between the surveys. The measurement  
of ‘Other opiates’ in Ireland in 2002/3 included nine drugs: Opium, Temgesic®, Diconal®, Napps, MSTs®, Pethidine, DF118®, (Dihydrocodeine), Buprenorphine and Morphine. In 2006/7 the category ‘Other opiates’ was extended to be 
consistent with Northern Ireland and included: Codeine, Feminax, Kapake, Diffs, Dikes, Peach, Fentanyl (Durogesic®, Sublimaze®, Actiq®), Oxycodone (Oxycontin®, Oxynorm®), and Buprehnorphine (Subutex®). In 2010/11 the category 
‘Other opiates’ also asked specifically about substances containing codeine such as Maxilief, Migraleve, Nurofen Plus, Codeine Phosp, Panadeine, Paracetamol/Caffeine/Codeine and Doxylamine, Paracodin, Paramol, Solpadeine, Solpadol,  
Syndol, Tylex, Uniflu Plus, Veganin Plus.
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Table 1.2: Prevalence of drug use in Ireland (%), by gender, 2002/3, 2006/7 and 2010/11
Lifetime use (%) Last year (%) Last month (%)
Male Female Male Female Male Female
02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Any illegal drug* 23.8 29.5 35.5ab 13.1 18.6 19.0b 7.8 9.8 10.4b 3.4 4.7 3.6 4.1 4.5 5.3 1.8 1.4 1.1
Cannabis 22.2 27.2 33.2ab 12.3 16.8 17.5b 7.2 8.8 9.1 2.9 3.9 2.9 3.4 4.1 4.7 1.7 1.2 0.9b
Heroin 0.7 0.5 1.2a 0.3 0.4 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0
Methadone 0.4 0.4 0.7 0.3 0.3 0.2 0.2 0.1 0.4 0.2 0.3 0.1 0.1 0.1 0.3 0.2 0.2 0.1
Other opiates† 2.0 4.8 35.2 3.9 7.6 42.4 0.4 1.5 24.0 0.5 2.8 31.7 0.2 0.9 11.1 0.1 1.0 17.1
Cocaine (incl crack) 4.3 7.1 9.9ab 1.6 3.5 3.8b 1.7 2.3 2.3 0.5 1.0 0.7 0.7 0.8 0.8 0.0 0.2 0.3b
Crack 0.5 0.8 1.0 0.1 0.3 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Cocaine powder 4.1 6.9 9.7ab 1.6 3.4 3.8b 1.7 2.2 2.3 0.5 1.0 0.7 0.7 0.8 0.8 0.0 0.2 0.3b
Amphetamines 4.0 4.6 6.6ab 1.9 2.4 2.5 0.6 0.5 0.4 0.2 0.3 0.4 0.2 0.1 0.1 0.1 0.1 0.0
Ecstasy 4.9 7.4 10.1b 2.6 3.6 3.7b 1.5 1.8 0.6ab 0.6 0.6 0.3 0.6 0.5 0.1ab 0.0 0.2 0.0
LSD 4.3 4.1 6.7ab 1.4 1.7 2.2 0.2 0.2 0.5 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0
Magic mushrooms 5.6 8.0 9.5b 2.0 3.8 3.6b 0.6 0.9 0.8 0.1 0.4 0.2 0.1 0.0 0.1 0.0 0.0 0.0
Solvents 2.2 2.3 3.8ab 1.1 1.4 1.3 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0
Poppers 3.8 4.3 6.0b 1.3 2.4 1.9 0.4 0.6 0.3 0.4 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.0
Sedatives or tranquillisers ** 8.1 12.4a ** 13.2 15.5a ** 3.7 5.7a ** 5.7 7.3a ** 2.4 2.3 ** 3.6 3.3
Anti-depressants ** 5.9 8.3a ** 12.6 12.4 ** 3.0 4.0 ** 5.7 5.6 ** 2.3 3.2 ** 4.0 5.0
New psychoactive substances *** *** *** *** *** *** *** *** 5.4 *** *** 1.6 *** *** *** *** *** ***
Tobacco 61.6 59.1 60.6 58.4 56.8 52.7ab 38.2 36.8 35.7 37.8 35.8 29.4ab 33.4 33.6 31.3 33.0 31.6 25.2ab
Alcohol 92.5 91.8 92.5 87.7 88.7 88.1 86.0 86.4 87.5 81.5 81.7 83.2 78.3 78.1 76.3 69.4 68.3 65.1ab
a Significant change (p<.05) between 2006/7 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
b Significant change (p<.05) between 2002/3 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** In 2002/3 the survey asked about use of sedatives, tranquillisers or anti-depressants together. Since 2006/7 the survey has asked about sedatives/tranquillisers and anti-depressants separately.
*** In 2010/11 the survey asked respondents about their use of New Psychoactive Substances for the first time. The survey asked only about use in the last 12 months.
† Tests for statistical significance between the prevalence of ‘Other opiates’ are not reported. As a result of measurement changes in 2006/7 and 2010/11, the ‘Other opiates’ category is not comparable between the surveys. The measurement  
of ‘Other opiates’ in Ireland in 2002/3 included nine drugs: Opium, Temgesic®, Diconal®, Napps, MSTs®, Pethidine, DF118®, (Dihydrocodeine), Buprenorphine and Morphine. In 2006/7 the category ‘Other opiates’ was extended to be 
consistent with Northern Ireland and included: Codeine, Feminax, Kapake, Diffs, Dikes, Peach, Fentanyl (Durogesic®, Sublimaze®, Actiq®), Oxycodone (Oxycontin®, Oxynorm®), and Buprehnorphine (Subutex®). In 2010/11 the category 
‘Other opiates’ also asked specifically about substances containing codeine such as Maxilief, Migraleve, Nurofen Plus, Codeine Phosp, Panadeine, Paracetamol/Caffeine/Codeine and Doxylamine, Paracodin, Paramol, Solpadeine, Solpadol,  
Syndol, Tylex, Uniflu Plus, Veganin Plus.
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Table 1.3: Prevalence of drug use in Ireland, by age, 2002/3, 2006/7 and 2010/11
Lifetime use (%) Last year (%) Last month (%)
15-34 35-64 15-34 35-64 15-34 35-64
02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Any illegal drug 25.9 31.4 35.7ab 11.8 17.6 20.6ab 9.8 12.2 12.3b 1.9 2.9 2.9b 5.2 5.0 5.3 0.9 1.2 1.6b
Cannabis 23.8 28.6 33.4ab 11.4 16.2 19.0ab 8.7 10.6 10.3 1.8 2.7 2.6 4.3 4.3 4.5 0.9 1.2 1.4
Heroin 0.7 0.5 0.7 0.3 0.4 0.8b 0.2 0.1 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1
Methadone 0.6 0.5 0.4 0.1 0.2 0.5b 0.4 0.2 0.3 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2
Other opiates† 2.9 4.6 37.0 3.0 7.6 40.2 0.6 1.7 28.3 0.4 2.5 27.6 0.1 0.8 14.2 0.2 1.1 14.1
Cocaine (incl crack) 4.7 8.2 9.4b 1.4 2.8 4.8ab 2.0 3.1 2.8 0.3 0.5 0.5 0.7 1.1 1.0 0.0 0.1 0.1
Crack 0.5 1.0 0.7b 0.2 0.2 0.5b 0.2 0.2 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0
Cocaine powder 4.5 7.9 9.3 1.4 2.7 4.7ab 2.0 2.9 2.7 0.3 0.5 0.5 0.7 1.0 1.0 0.0 0.1 0.1
Amphetamines 4.8 5.1 6.4 1.3 2.2 3.0b 0.8 0.8 0.8 0.1 0.1 0.1 0.3 0.2 0.0 0.0 0.0 0.1
Ecstasy 7.1 9.1 10.9b 0.7 2.3 3.7ab 2.3 2.4 0.9ab 0.0 0.2 0.2b 0.6 0.6 0.1ab 0.0 0.1 0.0
LSD 4.5 3.7 5.4a 2.0 2.2 3.7ab 0.2 0.3 0.6 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0
Magic mushrooms 5.9 8.6 8.2b 2.0 3.5 5.2ab 0.7 1.2 0.8 0.1 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.1
Solvents 3.3 3.2 3.8 0.2 0.8 1.5ab 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1
Poppers 4.7 5.5 6.2 0.7 1.4 2.2b 0.8 0.9 0.2ab 0.0 0.1 0.2b 0.2 0.1 0.0 0.0 0.0 0.1
Sedatives or tranquillisers ** 5.9 10.1a ** 14.7 16.9a ** 2.6 4.8a ** 6.5 7.8 ** 1.3 1.0 ** 4.5 4.1
Anti-depressants ** 7.3 6.8 ** 11.1 13.2a ** 3.4 3.0 ** 5.3 6.2 ** 2.3 2.3 ** 4.0 5.5ab
New psychoactive substances *** *** *** *** *** *** *** *** 6.7 *** *** 1.0 *** *** *** *** *** ***
Tobacco 57.4 56.3 53.0b 62.3 59.4 59.5 43.1 40.8 37.3b 33.4 32.3 28.8ab 36.9 36.0 31.3ab 29.8 29.7 25.9ab
Alcohol 92.0 90.4 89.4b 88.3 90.1 91.0b 86.5 86.3 86.3 81.3 82.0 84.5ab 74.6 73.7 70.9b 73.3 72.7 70.4
a Significant change (p<.05) between 2006/7 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
b Significant change (p<.05) between 2002/3 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** In 2002/3 the survey asked about use of sedatives, tranquillisers or anti-depressants together. Since 2006/7 the survey has asked about sedatives/tranquillisers and anti-depressants separately.
*** In 2010/11 the survey asked respondents about their use of New Psychoactive Substances for the first time. The survey asked only about use in the last 12 months.
† Tests for statistical significance between the prevalence of ‘Other opiates’ are not reported. As a result of measurement changes in 2006/7 and 2010/11, the ‘Other opiates’ category is not comparable between the surveys. The measurement  
of ‘Other opiates’ in Ireland in 2002/3 included nine drugs: Opium, Temgesic®, Diconal®, Napps, MSTs®, Pethidine, DF118®, (Dihydrocodeine), Buprenorphine and Morphine. In 2006/7 the category ‘Other opiates’ was extended to be 
consistent with Northern Ireland and included: Codeine, Feminax, Kapake, Diffs, Dikes, Peach, Fentanyl (Durogesic®, Sublimaze®, Actiq®), Oxycodone (Oxycontin®, Oxynorm®), and Buprehnorphine (Subutex®). In 2010/11 the category 
‘Other opiates’ also asked specifically about substances containing codeine such as Maxilief, Migraleve, Nurofen Plus, Codeine Phosp, Panadeine, Paracetamol/Caffeine/Codeine and Doxylamine, Paracodin, Paramol, Solpadeine, Solpadol,  
Syndol, Tylex, Uniflu Plus, Veganin Plus.
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Table 1.4: Prevalence of drug use in Ireland (%), by age, 2010/11
Lifetime use (%) Last year (%) Last month (%)
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 27.3 41.7 29.2 18.0 11.2 15.1 10.2 4.2 2.8 1.0 5.8 4.9 2.3 1.7 0.3
Cannabis 25.9 38.7 26.7 17.2 9.7 12.9 8.5 3.7 2.6 0.9 5.4 4.0 1.9 1.7 0.3
Heroin 0.3 1.0 0.8 1.3 0.1 0.3 0.1 0.1 0.2 0.0 0.0 0.0 0.1 0.2 0.0
Methadone 0.4 0.4 0.5 0.8 0.1 0.3 0.3 0.2 0.3 0.1 0.0 0.2 0.2 0.3 0.1
Other opiates† 31.7 40.8 41.8 41.3 36.4 24.5 31.0 30.7 28.5 21.8 12.5 15.4 15.9 15.5 9.8
Cocaine (including crack) 5.0 12.6 6.8 4.7 2.0 2.5 3.0 1.0 0.4 0.0 0.5 1.3 0.1 0.3 0.0
Crack 0.4 0.9 0.5 0.8 0.1 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
Cocaine powder 4.9 12.5 6.7 4.7 1.8 2.5 2.9 1.0 0.4 0.0 0.5 1.3 0.1 0.3 0.0
Amphetamines 3.8 8.3 4.4 3.0 1.1 1.5 0.3 0.0 0.3 0.0 0.1 0.0 0.0 0.2 0.0
Ecstasy 5.7 14.6 7.4 2.4 0.0 1.1 0.7 0.4 0.1 0.0 0.2 0.0 0.0 0.1 0.0
LSD 2.0 7.9 4.6 4.2 1.6 0.9 0.3 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0
Magic mushrooms 3.5 11.6 7.2 5.4 1.8 1.0 0.7 0.2 0.5 0.0 0.0 0.0 0.0 0.2 0.0
Solvents 2.7 4.6 2.3 1.3 0.8 0.6 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0
Poppers 3.5 8.1 3.4 2.3 0.2 0.2 0.2 0.4 0.1 0.1 0.0 0.0 0.3 0.1 0.0
Sedatives or tranquillisers** 5.0 13.7 14.5 16.1 21.4 2.7 6.3 6.9 7.2 9.9 0.5 1.4 2.8 3.8 6.6
Anti-depressants 4.4 8.5 13.9 14.1 11.2 2.6 3.3 6.2 6.9 5.3 1.6 2.8 5.6 6.2 4.5
New psychoactive substances *** *** *** *** *** 9.7 4.6 1.7 0.9 0.2 *** *** *** *** ***
Tobacco 46.1 57.4 57.8 59.3 60.7 35.1 38.8 32.1 30.7 23.7 29.2 33.5 28.6 28.1 22.0
Alcohol 83.2 93.8 92.9 90.8 88.6 81.7 89.6 87.6 84.8 79.5 65.9 74.5 72.1 71.4 66.8
a Significant change (p<.05) between 2006/7 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
b Significant change (p<.05) between 2002/3 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** In 2002/3 the survey asked about use of sedatives, tranquillisers or anti-depressants together. Since 2006/7 the survey has asked about sedatives/tranquillisers and anti-depressants separately.
*** In 2010/11 the survey asked respondents about their use of New Psychoactive Substances for the first time. The survey asked only about use in the last 12 months.
† Tests for statistical significance between the prevalence of ‘Other opiates’ are not reported. As a result of measurement changes in 2006/7 and 2010/11, the ‘Other opiates’ category is not comparable between the surveys. The measurement  
of ‘Other opiates’ in Ireland in 2002/3 included nine drugs: Opium, Temgesic®, Diconal®, Napps, MSTs®, Pethidine, DF118®, (Dihydrocodeine), Buprenorphine and Morphine. In 2006/7 the category ‘Other opiates’ was extended to be 
consistent with Northern Ireland and included: Codeine, Feminax, Kapake, Diffs, Dikes, Peach, Fentanyl (Durogesic®, Sublimaze®, Actiq®), Oxycodone (Oxycontin®, Oxynorm®), and Buprehnorphine (Subutex®). In 2010/11 the category 
‘Other opiates’ also asked specifically about substances containing codeine such as Maxilief, Migraleve, Nurofen Plus, Codeine Phosp, Panadeine, Paracetamol/Caffeine/Codeine and Doxylamine, Paracodin, Paramol, Solpadeine, Solpadol,  
Syndol, Tylex, Uniflu Plus, Veganin Plus.
17 National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch (PHIRB)
Drug use in Ireland and Northern Ireland: first results from the 2010/11 Drug Prevalence Survey
Table 1.5a: Lifetime prevalence of drug use in Ireland (%), by gender and age, 2010/11
Lifetime use (%)
Male Female
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 35.8 51.8 38.5 24.8 17.0 18.9 32.0 19.8 11.2 5.3
Cannabis 34.2 48.2 35.5 24.1 15.3 17.8 29.6 17.9 10.4 4.2
Heroin 0.4 1.5 1.1 2.4 0.2 0.2 0.5 0.5 0.2 0.0
Methadone 0.7 0.8 0.5 1.5 0.2 0.1 0.1 0.5 0.2 0.0
Other opiates† 28.9 34.8 39.9 37.3 33.7 34.5 46.7 43.7 45.4 39.0
Cocaine (including crack) 6.9 17.3 9.8 8.3 3.1 3.2 8.0 3.8 1.0 0.8
Crack 0.5 1.5 0.8 1.7 0.2 0.2 0.5 0.2 0.0 0.0
Cocaine powder 6.7 17.2 9.6 8.3 2.9 3.2 8.0 3.8 1.0 0.8
Amphetamines 5.0 11.7 6.4 5.7 1.3 2.5 5.1 2.4 0.2 0.9
Ecstasy 7.8 21.3 10.9 4.5 0.0 3.7 8.1 3.9 0.3 0.0
LSD 3.7 11.4 6.1 7.2 2.8 0.2 4.5 3.1 1.2 0.5
Magic mushrooms 4.7 17.7 9.6 8.7 2.2 2.4 5.7 4.8 2.1 1.4
Solvents 4.0 7.3 3.4 1.9 0.8 1.5 2.1 1.1 0.6 0.8
Poppers 4.9 12.2 5.3 3.8 0.3 2.0 4.2 1.4 0.8 0.0
Sedatives and tranquillisers 5.9 11.8 12.8 13.7 18.7 4.2 15.5 16.3 18.4 24.2
Anti-depressants 3.4 4.9 11.4 12.4 10.3 5.3 11.9 16.4 15.8 12.2
New psychoactive substances ** ** ** ** ** ** ** ** ** **
Alcohol 84.2 96.4 94.8 93.1 91.8 82.2 91.2 90.9 88.6 85.4
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** New psychoactive substances were included for the first time in the 2010/11 Drug Prevalence Survey. The survey asked only about use in the last year. (see Methodology section for a description of measurement).
† A change in the measurement of ‘Other opiates’ occurred in the 2010/11 survey. Please see Methodology section for further details.
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Table 1.5b: Last year prevalence of drug use in Ireland (%), by gender and age, 2010/11
Last year (%)
Male Female
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 20.4 16.0 6.6 5.0 1.7 9.9 4.7 1.8 0.7 0.3
Cannabis 17.7 13.9 5.8 4.5 1.5 8.1 3.3 1.6 0.7 0.3
Heroin 0.4 0.1 0.1 0.4 0.0 0.1 0.1 0.1 0.0 0.0
Methadone 0.6 0.5 0.2 0.6 0.2 0.1 0.1 0.2 0.0 0.0
Other opiates† 19.3 25.6 28.8 23.7 20.5 29.6 36.2 32.7 33.3 23.1
Cocaine (including crack) 3.9 4.3 1.7 0.7 0.0 1.1 1.7 0.3 0.1 0.0
Crack 0.0 0.3 0.0 0.4 0.0 0.1 0.2 0.1 0.0 0.0
Cocaine powder 3.9 4.0 1.7 0.7 0.0 1.1 1.7 0.3 0.1 0.0
Amphetamines 1.4 0.2 0.0 0.6 0.0 1.5 0.3 0.0 0.0 0.0
Ecstasy 1.3 0.9 0.8 0.0 0.0 1.0 0.4 0.1 0.1 0.0
LSD 1.6 0.4 0.1 0.4 0.0 0.1 0.3 0.0 0.0 0.0
Magic mushrooms 1.4 1.2 0.3 1.0 0.0 0.7 0.2 0.0 0.1 0.0
Solvents 0.7 0.0 0.0 0.4 0.0 0.5 0.0 0.0 0.0 0.0
Poppers 0.0 0.3 0.8 0.0 0.2 0.4 0.1 0.0 0.1 0.0
Sedatives and tranquillisers 3.5 5.3 5.7 5.9 8.6 1.9 7.3 8.2 8.4 11.2
Anti-depressants 2.1 2.3 5.5 5.2 5.4 3.1 4.3 6.9 8.7 5.2
New psychoactive substances** 14.9 6.9 2.7 1.4 0.3 4.5 2.2 0.6 0.5 0.1
Alcohol 83.1 92.7 89.7 85.4 83.1 80.3 86.6 85.4 84.2 75.9
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** New psychoactive substances were included for the first time in the 2010/11 Drug Prevalence Survey. The survey asked only about use in the last year. (see Methodology section for a description of measurement).
† A change in the measurement of ‘Other opiates’ occurred in the 2010/11 survey. Please see Methodology section for further details.
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Table 1.5c: Last month prevalence of drug use in Ireland (%), by gender and age, 2010/11
Last month use (%)
Male Female
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 9.0 8.5 4.0 2.8 0.4 2.7 1.5 0.5 0.5 0.3
Cannabis 8.3 7.1 3.4 2.8 0.4 2.5 0.9 0.4 0.5 0.3
Heroin 0.0 0.1 0.1 0.4 0.0 0.1 0.0 0.1 0.0 0.0
Methadone 0.0 0.3 0.2 0.6 0.2 0.1 0.1 0.1 0.0 0.0
Other opiates† 10.1 10.4 13.3 12.2 9.0 14.8 20.3 18.4 18.7 10.6
Cocaine (including crack) 0.7 2.1 0.1 0.4 0.0 0.4 0.5 0.1 0.1 0.0
Crack 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cocaine powder 0.7 2.1 0.1 0.4 0.0 0.4 0.5 0.1 0.1 0.0
Amphetamines 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0
Ecstasy 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0
LSD 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Magic mushrooms 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0
Solvents 0.1 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0
Poppers 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.1 0.0
Sedatives and tranquillisers 0.5 1.3 1.7 3.1 5.7 0.5 1.6 3.9 4.4 7.4
Anti-depressants 0.7 1.9 4.7 4.9 3.8 2.5 3.6 6.5 7.6 5.1
New psychoactive substances ** ** ** ** ** ** ** ** ** **
Alcohol 68.1 82.9 76.5 75.5 75.4 63.7 66.2 67.6 67.2 58.2
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** New psychoactive substances were included for the first time in the 2010/11 Drug Prevalence Survey. The survey asked only about use in the last year. (see Methodology section for a description of measurement).
† A change in the measurement of ‘Other opiates’ occurred in the 2010/11 survey. Please see Methodology section for further details.
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Table 2.1: Prevalence of drug use (adults 15-64 yrs) in Northern Ireland, 2002/3, 2006/7 and 2010/11
Lifetime prevalence Last year prevalence Last month prevalence
02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Any illegal drug* 20.0 28.0 27.3b 6.4 9.4 6.6ab 3.4 3.6 3.3
Cannabis 16.8 24.7 24.0b 5.4 7.2 5.1ab 2.9 2.6 2.7
Heroin 0.2 0.5 0.4 0.0 0.1 0.1 0.0 0.1 0.0
Methadone 0.1 0.1 1.0a 0.0 0.0 0.4a 0.0 0.0 0.0
Other opiates 18.0 20.2 15.6a 8.0 8.4 6.4a 4.1 4.9 3.6
Cocaine (including crack) 1.6 5.2 6.7b 0.5 1.9 1.5b 0.1 0.3 0.5
Crack 0.2 0.4 0.9 0.0 0.0 0.2 0.0 0.0 0.0
Cocaine powder 1.6 5.1 6.5b 0.5 1.9 1.5b 0.1 0.3 0.5
Amphetamines 4.0 5.8 6.3b 0.8 1.0 1.1 0.2 0.3 0.3
Ecstasy 5.8 7.7 8.8b 1.6 1.8 1.1 0.5 0.8 0.3
LSD 4.5 6.6 5.1b 0.1 0.2 0.2 0.0 0.0 0.0
Magic mushrooms 4.3 6.7 5.8b 0.2 0.2 0.2 0.0 0.0 0.0
Solvents 2.9 3.5 3.9 0.2 0.2 0.1 0.1 0.1 0.0
Poppers 5.5 7.8 8.8b 0.5 1.3 0.8b 0.2 0.3 0.1
Sedatives and tranquillisers -- 20.2 20.7 -- 9.2 11.0 -- 7.1 8.0
Anti-depressants -- 21.0 21.9 -- 9.1 12.0a -- 7.5 10.2a
Mephedrone -- -- 2.0 -- -- 1.1 -- -- 0.1
Legal Highs -- -- 2.4 -- -- 1.0 -- -- 0.2
a Significant change (p < 0.5) between 2006/7 and 2010/11.
b Significant change (p < 0.5) between 2002/3 and 2010/11.
* For this study, “any illegal drug” refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, LSD, magic mushrooms, poppers and solvents.
-- Comparative figures are not available. In 2002/3 respondents were asked about their use of sedatives, tranquillisers or anti-depressants together and thus prevalence rates are not available for the separate categories. From 2006/7 onwards 
respondents were asked about their use of sedative and tranquillisers and anti-depressants separately. Mephedrone and Legal Highs were asked in the survey for the first-time in 2010/11 and thus no comparisons are available.
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Table 2.2: Prevalence of drug use in Northern Ireland, by gender, 2002/3, 2006/7 and 2010/11
Lifetime prevalence Last year prevalence Last month prevalence
Males Females Males Females Males Females
02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Any illegal drug* 26.7 33.9 32.3b 13.5 22.1 22.4b 9.7 13.7 9.2ab 3.1 5.2 3.9b 5.7 4.9 5.1 1.1 2.4 1.6b
Cannabis 23.3 30.1 29.2b 10.5 19.3 18.8b 8.7 10.3 7.4 2.2 4.1 2.7b 5.1 3.7 4.4 0.8 1.6 1.1b
Heroin 0.4 0.6 0.6 0.0 0.4 0.1b 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0
Methadone 0.2 0.1 1.5a 0.1 0.1 0.5 0.0 0.0 0.6a 0.1 0.0 0.3 0.0 0.0 0.1 0.1 0.0 0.0
Other opiates 16.4 17.4 13.9 19.5 23.0 17.4ab 6.9 8.0 5.8 9.0 8.7 7.0 3.1 5.1 3.3b 5.2 4.7 3.8
Cocaine (including crack) 2.8 7.4 8.8b 0.5 2.9 4.5b 1.0 2.8 2.1b 0.1 0.9 0.9b 0.2 0.7 0.9 0.0 0.0 0.2
Crack 0.4 0.4 1.2a 0.1 0.4 0.6b 0.1 0.1 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1
Cocaine powder 2.7 7.3 8.7b 0.5 2.9 4.3b 0.9 2.8 2.1b 0.1 0.9 0.8b 0.2 0.7 0.9 0.0 0.0 0.1
Amphetamines 6.3 7.3 8.1 1.8 4.4 4.6b 1.4 1.1 1.5 0.2 0.9 0.8b 0.5 0.4 0.5 0.0 0.2 0.2
Ecstasy 8.3 9.9 11.1 3.3 5.5 6.5b 2.7 2.4 1.9 0.6 1.2 0.4 0.9 0.8 0.5 0.1 0.7 0.1b
LSD 7.0 9.7 6.9b 2.0 3.5 3.3b 0.0 0.2 0.3 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.0
Magic mushrooms 6.3 11.2 8.6b 2.4 2.4 3.0 0.4 0.1 0.2 0.1 0.3 0.1 0.1 0.1 0.0 0.0 0.0 0.0
Solvents 4.1 5.1 4.2 1.7 2.0 3.7a 0.3 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.0
Poppers 7.3 10.9 10.0b 3.8 4.9 7.6a 0.7 2.3 1.1b 0.3 0.3 0.4 0.2 0.6 0.1 0.1 0.0 0.1
Sedatives and tranquillisers -- 18.1 17.2 -- 22.3 24.1 -- 8.2 9.3 -- 10.2 12.7 -- 5.7 7.3 -- 8.4 8.7
Anti-depressants -- 13.4 15.3 -- 28.4 28.4 -- 5.8 8.9a -- 12.4 15.2 -- 4.2 7.6a -- 10.7 12.8
Mephedrone -- -- 3.1 -- -- 0.9 -- -- 1.9 -- -- 0.3 -- -- 0.1 -- -- 0.0
Legal Highs -- -- 3.0 -- -- 1.8 -- -- 1.6 -- -- 0.3 -- -- 0.3 -- -- 0.1
a Significant change (p < 0.5) between 2006/7 and 2010/11.
b Significant change (p < 0.5) between 2002/3 and 2010/11.
* For this study, “any illegal drug” refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, LSD, magic mushrooms, poppers and solvents.
-- Comparative figures are not available. In 2002/3 respondents were asked about their use of sedatives, tranquillisers or anti-depressants together and thus prevalence rates are not available for the separate categories in 2006/7 and 2010/11 
survey respondents were asked about their use of sedative and tranquillisers and anti-depressants separately. Mephedrone and Legal Highs were asked in the survey for the first-time in 2010/11 and thus no comparisons are available.
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Table 2.3: Prevalence of drug use in Northern Ireland, by age, 2002/3, 2006/7 and 2010/11
Lifetime prevalence Last year prevalence Last month prevalence
15-34 35-64 15-34 35-64 15-34 35-64
02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Any illegal drug* 30.9 40.2 36.9b 11.5 19.3 20.4b 11.6 17.3 11.8ab 2.2 3.7 2.7b 6.1 5.9 5.7 1.2 2.0 1.7b
Cannabis 25.1 35.0 32.2b 10.3 17.3 18.0b 9.8 12.4 9.4 2.0 3.3 1.9ab 5.4 3.7 4.6 1.0 1.8 1.3b
Heroin 0.3 0.6 0.2 0.1 0.4 0.5 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0
Methadone 0.2 0.1 2.0a 0.1 0.1 0.3 0.0 0.0 0.8a 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1
Other opiates† 17.9 14.4 13.0 18.0 24.7 17.6ab 7.5 7.1 5.6 8.3 9.3 6.9a 3.3 3.6 2.9 4.8 5.8 4.0a
Cocaine (including crack) 2.9 9.1 11.2b 0.6 2.3 3.4b 1.0 3.5 2.5b 0.1 0.7 0.8b 0.2 0.6 0.6 0.0 0.2 0.5
Crack 0.4 0.6 1.1 0.1 0.3 0.7 0.1 0.0 0.3 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1
Cocaine powder 2.9 9.1 10.8b 0.6 2.2 3.3b 0.9 3.5 2.5b 0.1 0.7 0.7b 0.2 0.6 0.6 0.0 0.2 0.4
Amphetamines 7.2 9.1 8.9 1.5 3.4 4.4b 1.5 1.7 1.5 0.2 0.4 0.9 0.3 0.3 0.3 0.1 0.3 0.4
Ecstasy 11.3 14.3 14.2 1.4 2.9 4.8ab 3.3 3.4 2.0 0.4 0.6 0.4 1.1 1.4 0.6 0.1 0.3 0.1
LSD 7.8 9.4 5.7a 1.9 4.5 4.6b 0.1 0.0 0.4 0.0 0.3 0.1b 0.0 0.0 0.0 0.0 0.1 0.1
Magic mushrooms 6.4 8.3 7.7 2.7 5.6 4.4b 0.3 0.5 0.3 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0
Solvents 5.4 5.5 5.2 1.0 2.1 3.1b 0.3 0.4 0.2 0.0 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.0
Poppers 10.9 14.0 13.6 1.3 3.4 5.2ab 1.1 2.7 1.5b 0.0 0.2 0.2 0.3 0.7 0.2 0.0 0.0 0.0
Sedatives and tranquillisers -- 11.7 13.6 -- 26.5 25.8 -- 4.6 6.4 -- 12.6 14.3 -- 2.3 3.6 -- 10.7 11.2
Anti-depressants -- 13.6 13.6 -- 26.6 28.0 -- 5.8 7.1 -- 11.7 15.7a -- 4.2 5.0 -- 10.0 14.0a
Mephedrone -- -- 4.3 -- -- 0.4 -- -- 2.2 -- -- 0.3 -- -- 0.1 -- -- 0.0
Legal Highs -- -- 4.8 -- -- 0.6 -- -- 2.0 -- -- 0.2 -- -- 0.4 -- -- 0.0
a Significant change (p < 0.5) between 2006/7 and 2010/11.
b Significant change (p < 0.5) between 2002/3 and 2010/11.
* For this study, “any illegal drug” refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, LSD, magic mushrooms, poppers and solvents.
-- Comparative figures are not available. In 2002/3 respondents were asked about their use of sedatives, tranquillisers or anti-depressants together and thus prevalence rates are not available for the separate categories in 2006/7 and 2010/11 
survey respondents were asked about their use of sedative and tranquillisers and anti-depressants separately. Mephedrone and Legal Highs were asked in the survey for the first-time in 2010/11 and thus no comparisons are available.
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Table 2.4: Prevalence of drug use in Northern Ireland, by age, 2010/11
Lifetime use Last year Last month
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 31.5 42.7 30.5 19.4 8.1 13.4 10.2 5.5 1.7 0.3 6.5 4.7 3.0 1.3 0.3
Cannabis 26.8 38.0 26.6 17.2 7.4 10.8 7.9 3.7 1.3 0.3 5.2 4.0 2.3 1.1 0.3
Heroin 0.0 0.4 0.4 0.9 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
Methadone 2.6 1.3 0.9 0.0 0.0 0.9 0.6 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0
Other opiates 10.7 15.4 21.2 17.5 12.8 4.9 6.4 9.0 6.7 4.3 3.2 2.7 5.5 3.6 2.5
Cocaine (including crack) 11.7 10.6 6.7 2.4 0.2 3.1 1.8 1.4 0.8 0.0 0.8 0.5 0.9 0.4 0.0
Crack 1.0 1.2 1.1 0.9 0.0 0.3 0.3 0.1 0.4 0.0 0.0 0.0 0.1 0.0 0.0
Cocaine powder 11.3 10.3 6.7 2.2 0.2 3.1 1.8 1.3 0.8 0.0 0.8 0.5 0.8 0.4 0.0
Amphetamines 8.3 9.6 8.7 2.9 0.5 1.5 1.5 1.8 0.6 0.0 0.4 0.2 0.6 0.4 0.0
Ecstasy 12.3 16.3 10.4 2.4 0.3 2.7 1.3 1.0 0.2 0.0 0.7 0.4 0.2 0.2 0.0
LSD 3.0 8.6 8.6 3.0 1.3 0.6 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0
Magic mushrooms 5.0 10.5 6.4 4.8 1.3 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
Solvents 4.1 6.3 5.8 1.6 1.1 0.2 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0
Poppers 11.9 15.5 10.8 2.9 0.5 1.8 1.1 0.4 0.2 0.0 0.3 0.2 0.0 0.0 0.0
Sedatives and tranquillisers 12.4 14.8 22.2 27.2 29.1 5.5 7.4 11.0 15.1 17.8 2.5 4.7 7.8 12.2 14.7
Anti-depressants 10.9 16.5 27.1 32.3 23.9 6.3 8.0 14.6 17.8 14.5 3.2 6.9 13.3 15.6 13.0
Mephedrone 5.7 2.8 1.0 0.0 0.0 3.1 1.2 0.8 0.0 0.0 0.3 0.0 0.0 0.0 0.0
Legal Highs 5.9 3.6 1.0 0.7 0.0 3.3 0.6 0.4 0.2 0.0 0.8 0.0 0.0 0.0 0.0
* For this study, “any illegal drug” refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, LSD, magic mushrooms, poppers and solvents.
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Table 2.5: Lifetime prevalence of drug use in Northern Ireland, by gender and age, 2010/11
Lifetime prevalence
Males Females
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 34.6 48.4 37.7 24.3 11.4 28.3 37.1 23.4 14.6 4.9
Cannabis 31.5 44.0 33.0 21.7 11.4 21.9 31.9 20.4 12.9 3.5
Heroin 0.0 0.8 0.4 1.9 0.0 0.0 0.0 0.5 0.0 0.0
Methadone 3.9 1.6 1.5 0.0 0.0 1.2 1.1 0.2 0.0 0.0
Other opiates 8.8 12.8 20.3 15.2 12.2 12.8 17.9 22.2 19.7 13.4
Cocaine (including crack) 14.0 13.0 9.9 4.2 0.3 9.2 8.2 3.5 0.6 0.0
Crack 0.7 1.6 1.7 1.9 0.0 1.3 0.8 0.6 0.0 0.0
Cocaine powder 14.0 12.6 9.9 3.8 0.3 8.5 7.9 3.5 0.6 0.0
Amphetamines 7.4 12.2 13.0 5.0 1.0 9.2 7.0 4.6 1.0 0.0
Ecstasy 14.5 19.6 13.7 4.2 0.7 10.0 13.0 7.1 0.6 0.0
LSD 3.0 10.9 13.7 3.9 1.9 2.9 6.3 3.7 2.2 0.8
Magic mushrooms 7.7 14.6 11.0 6.7 1.4 2.2 6.5 2.0 3.0 1.2
Solvents 2.5 4.9 8.9 2.2 1.6 5.7 7.7 2.9 1.1 0.7
Poppers 9.7 17.1 15.0 4.6 1.1 14.2 13.9 6.7 1.3 0.0
Sedatives and tranquillisers 10.8 10.7 19.1 23.6 23.7 14.2 18.8 25.1 30.6 34.4
Anti-depressants 6.5 10.4 20.7 23.4 16.8 15.5 22.5 33.3 40.8 30.8
Mephedrone 8.2 4.3 2.0 0.0 0.0 3.1 1.3 0.0 0.0 0.0
Legal Highs 7.5 3.9 1.5 1.1 0.0 4.3 3.3 0.6 0.3 0.0
* For this study, “any illegal drug” refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, LSD, magic mushrooms, poppers and solvents.
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Table 2.6: Last year prevalence of drug use in Northern Ireland, by gender and age, 2010/11
Last year prevalence
Males Females
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 17.2 14.1 8.5 3.1 0.3 9.4 6.3 2.5 0.3 0.2
Cannabis 15.8 10.9 5.4 2.3 0.3 5.5 4.9 2.0 0.3 0.2
Heroin 0.0 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0
Methadone 1.3 0.4 0.9 0.0 0.0 0.5 0.8 0.0 0.0 0.0
Other opiates 4.6 5.6 8.4 6.0 3.8 5.3 7.2 9.6 7.4 4.8
Cocaine (including crack) 3.5 2.3 2.6 1.6 0.0 2.6 1.4 0.3 0.0 0.0
Crack 0.0 0.0 0.0 0.8 0.0 0.6 0.5 0.3 0.0 0.0
Cocaine powder 3.5 2.3 2.6 1.6 0.0 2.6 1.4 0.0 0.0 0.0
Amphetamines 0.6 1.9 3.6 1.2 0.0 2.5 1.1 0.0 0.0 0.0
Ecstasy 4.7 1.9 1.6 0.4 0.0 0.6 0.7 0.5 0.0 0.0
LSD 0.6 0.4 0.0 0.4 0.0 0.6 0.0 0.0 0.0 0.0
Magic mushrooms 0.6 0.0 0.0 0.4 0.0 0.5 0.0 0.0 0.0 0.0
Solvents 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0
Poppers 1.8 2.0 0.8 0.4 0.0 1.7 0.3 0.0 0.0 0.0
Sedatives and tranquillisers 5.7 4.7 9.5 13.5 14.6 5.2 10.2 12.3 16.7 20.9
Anti-depressants 5.8 5.6 10.1 12.3 11.4 6.7 10.3 18.9 23.2 17.6
Mephedrone 5.0 2.1 1.7 0.0 0.0 1.0 0.3 0.0 0.0 0.0
Legal Highs 4.9 1.2 0.8 0.4 0.0 1.5 0.0 0.0 0.0 0.0
* For this study, “any illegal drug” refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, LSD, magic mushrooms, poppers and solvents.
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Table 2.7: Last month prevalence of drug use in Northern Ireland, by gender and age, 2010/11
Last month prevalence
Males Females
15-24 25-34 35-44 45-54 55-64 15-24 25-34 35-44 45-54 55-64
Any illegal drug* 10.0 6.9 4.6 2.4 0.3 3.0 2.6 1.4 0.3 0.2
Cannabis 9.1 5.7 3.5 1.9 0.3 1.1 2.3 1.1 0.3 0.2
Heroin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Methadone 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Other opiates 3.3 2.9 5.3 2.2 2.4 3.1 2.4 5.7 4.9 2.6
Cocaine (including crack) 1.5 0.4 1.6 0.8 0.0 0.0 0.6 0.3 0.0 0.0
Crack 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0
Cocaine powder 1.5 0.4 1.6 0.8 0.0 0.0 0.6 0.0 0.0 0.0
Amphetamines 0.0 0.4 1.2 0.8 0.0 0.7 0.0 0.0 0.0 0.0
Ecstasy 0.8 0.8 0.4 0.4 0.0 0.6 0.0 0.0 0.0 0.0
LSD 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0
Magic mushrooms 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Solvents 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Poppers 0.0 0.4 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0
Sedatives and tranquillisers 3.8 3.1 6.9 11.3 12.7 1.2 6.3 8.6 12.9 16.6
Anti-depressants 3.4 4.9 9.7 11.1 10.0 3.0 8.9 16.8 20.0 16.0
Mephedrone 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Legal Highs 1.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0
* For this study, “any illegal drug” refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, LSD, magic mushrooms, poppers and solvents.
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Table 3.1: Island of Ireland – Lifetime, last year and last month prevalence (%), 2002/3, 2006/7 and 2010/11
Lifetime use (%) Last year (%) Last month (%)
Drug 2002/3 2006/7 2010/11 2002/3 2006/7 2010/11 2002/3 2006/7 2010/11
Any illegal drug* 18.9 25.1 27.3ab 5.8 7.8 6.9b 3.1 3.1 3.2
Cannabis 17.2 22.7 24.9ab 5.1 6.5 5.7 2.7 2.6 2.8
Heroin 0.2 0.4 0.6 0.1 0.1 0.1 0.1 0.0 0.1
Methadone 0.3 0.3 0.6ab 0.2 0.1 0.3a 0.1 0.1 0.1
Cocaine (including crack) 2.6 5.2 6.8ab 0.9 1.7 1.5b 0.2 0.5 0.5b
Crack 0.3 0.5 0.7b 0.1 0.1 0.2 0.0 0.0 0.0
Cocaine powder 2.5 5.1 6.7ab 0.9 1.7 1.5b 0.2 0.5 0.5b
Amphetamines 3.3 4.2 5.0ab 0.5 0.6 0.6 0.2 0.2 0.1
Ecstasy 4.3 6.0 7.4ab 1.3 1.4 0.7ab 0.4 0.4 0.1ab
LSD 3.4 3.9 4.6b 0.1 0.2 0.3b 0.0 0.0 0.0
Magic mushrooms 4.0 6.0 6.3b 0.4 0.5 0.4 0.1 0.0 0.0
Solvents 2.0 2.4 3.0b 0.1 0.1 0.1 0.0 0.0 0.1
Poppers 3.4 4.6 5.3b 0.4 0.7 0.4a 0.1 0.2 0.1
Sedatives or tranquillisers ** 13.3 15.8a ** 6.0 7.8a ** 4.1 4.3
Anti-depressants ** 12.5 13.6 ** 5.7 6.8a ** 4.3 5.8a
a Significant change (p<.05) between 2006/7 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
b Significant change (p<.05) between 2002/3 and 2010/11. When considering the results it should be borne in mind that statistical significance does not imply that the change is of practical importance.
* Any illegal drugs refers to amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, poppers and solvents.
** In 2002/3 the survey asked respondents about use of sedatives, tranquillisers and anti-depressants together. Since 2006/7 the survey has asked separate questions for use of sedatives or tranquillisers and for use of anti-depressants.
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